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1. Introduction
Psoriasis is a common, disfiguring, inflammatory, and chronic skin disorder 
with a worldwide distribution, but is more common in the Caucasians of the 
western world [1]. The incidence of psoriasis has been estimated by census studies. 
The general impression is that the highest incidence is in Europeans, and the lowest 
in Asians from the East [2].
The cause of psoriasis is unknown, although, environmental and genetic 
factors appear to play a major role in it. There is undoubtedly a genetic compo-
nent to the progress of disease; many environmental factors have been linked to 
psoriasis, and have been involved in induction of the disease process and getting 
worse of pre-existing disease. These factors include physical trauma [3], infec-
tions [4], stress [5], certain drugs (such as beta-blockers, lithium, antimalarials, 
and systemic steroids) [6], hypocalcemia [7], alcohol consumption, smoking [8], 
and climate [9].
There is enormous evidence that psoriasis has an important genetic factor, as it 
was noted that the disease tended to run in families. Perhaps, the most robust data 
supporting a genetic basis to psoriasis come from studies examining concordance 
for the disease in twins. Initial studies of the class I human leukocyte antigens 
(HLA) disclosed an association of psoriasis with B13, B17, and B37. Not long ago, 
B57 has also been found to be related with psoriasis. Nevertheless, the extreme con-
nection of the class I HLA is with Cw6 [10, 11].
The diagnosis of psoriasis is mainly clinical (skin rash, nail changes, and joint 
involvement). There are different clinical types of psoriasis; the most common of 
which is chronic plaque psoriasis, affecting most of patients [12].
Although congenital psoriasis is very rare, the first manifestation of psoria-
sis may occur at any age, but it is rare under the age of 10 years. Most forms of 
psoriasis are present before the age of 30 (Figure 1) [15]. Chronicity, inflam-
mation, and hyperproliferation are the cardinal features of psoriasis in child-
hood [16].
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1. Well circumscribed, red, scaly plaques, either as single lesions or as generalized disease.
2. Lots of small lesions, appearing more or less generally over the body, particularly over 
the trunk and proximal extremities, predominantly induced in children and young 
adults, and after acute streptococcal infections [17].
3. Plaques associated with gross hyperkeratosis.
4. May be usefully used to describe phases of the disease, in which activity is marked and 
the course of disease is unforeseeable. The border of lesions in unstable phase is not 
well-demarcated [13].
5. Two forms exist [18]. In the first form, chronic lesions may evolve gradually into an 
exfoliative phase, and can be regarded as extensive plaque psoriasis involving all, or 
Figure 1. 
Summary of clinical presentations [13, 14].
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almost all, the cutaneous surface. The second form is part of the spectrum of “unstable” 
psoriasis [19].
6. Pustular psoriasis: I. Generalized (von Zumbusch)—frequently seen in young 
individuals; develop independently or as a complication of plaque type, such as 
secondary to abrupt withdrawal of systemic steroid therapy, mediating triggering 
factors, hypocalcemia; sudden onsets on an erythematous background associated 
with general symptoms (fever, lethargy, and arthralgia); high sedimentation rate; 
leukocytosis; lymphopenia, and negative nitrogen balance; during pregnancy 
known as Impetigo herpetiformis [20]. II. Localized—incidence low as compared with 
psoriasis vulgaris; chronic relapsing eruption limited to palms and soles; numerous 
sterile, yellow, and deep-seated pustules that evolve into dusky-red crusts; consid-
ered by some as localized pustular psoriasis (Barber-type) and by others a separate 
entity [21].
7. Very thick plaques develop, especially at the occiput, not a frequent cause of alopecia.
8. Solitary patch on the glans without scales, but its color and well-defined edge is 
characteristic.
9. Involving the groins, vulva, axillae, submammary folds, gluteal cleft, and other body 
folds in older adults.
10. Typical scaly patches; less well-defined plaques resembling lichen simplex or hyper-
keratotic eczema; or as a pustulosis.
11. Can present without concomitant skin plaques; pitting, distal onycholysis, subungual 
hyperkeratosis, oil drop sign, splinter hemorrhages, leukonychia, crumbling, red 
lunula; a predictor of psoriatic arthritis.
12. May occur in the presence of other typical lesions, as part of the Koebner phenomenon, 
or a Koebner reaction at a site of herpes zoster, respectively.
13. Involving the scalp, eyebrows, and the region of the ears.
14. True mucosal involvement by psoriasis appears to be rare, but has been associated with 
cutaneous involvement by pustular, erythrodermic, and plaque forms [22].
15. Blepharitis, conjunctivitis, keratitis, xerosis, symblepharon, and trichiasis have been 
recorded. Chronic uveitis particularly in patients with psoriatic arthritis [23].
16. Rarely skin infection.
17. Very variable in psoriasis, ranging from complete absence to severe pruritus; more 
common in unstable forms.
18. Affects approximately 30% of patients with psoriasis [24]; variable presentation; 
common feature is dactylitis, in which the entire digit becomes swollen, often 
called a sausage digit; can affect small joints and large joints; either oligoarticular or 
polyarticular; can also affect the axial skeleton, presenting as inflammatory back 
pain [25].
19. More commonly in male patients with severe psoriasis.
20. Rare, post-streptococcal guttate psoriasis to be associated with glomerulonephritis [26].
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21. Severe abnormalities of liver function may occur in erythrodermic or pustular psoria-
sis, and are likely to be related to drugs, alcohol intake [27].
22. Apical pulmonary fibrosis [28].
23. Amyloidosis [29].
The differential diagnosis will depend on the type of psoriasis and the site 
involved (Table 1).
Treatment goals include improvement of skin, nail, and joint lesions, and 
enhancement of the quality of life. Moderate to severe psoriasis is distinguished 
from mild disease, that is refractory to topical monotherapy (Table 2) [12].
Term Definition
Mild plaque 
psoriasis
Minimal impact on the patient’s quality of life (QoL); acceptable symptomatic 
control by topical monotherapy
Moderate plaque 
psoriasis
No acceptable symptomatic control by standard topical therapy and/or significant 
impact on the patient’s QoL
Severe plaque 
psoriasis
No acceptable symptomatic control by standard topical therapy and that causes 
severe degradation of the patient’s QoL
Adopted from [12].
Table 2. 
Criteria for assessing the severity of plaque psoriasis.
Type Differential diagnosis
Guttate psoriasis Maculopapular drug eruption, secondary syphilis, pityriasis rosea
Small plaques Seborrheic dermatitis; Lichen simplex chronicus (LSC); Tinea corporis; cutaneous 
T-cell lymphoma (CTCL); Psoriasiform drug eruptions
Large plaques Dermatophytosis; CTCL
Scalp Dermatophytosis; Seborrheic dermatitis
Inverse Intertrigo; dermatophytosis; candidiasis; Extramammary Paget’s Disease 
(EMPD); Glucagonoma syndrome; Hand-Schüller-Christian disease 
(histiocytosis), familial benign pemphigus (Hailey-Hailey disease).
Nail involvement Nail fungal infections
Erythrodermic type Generalized eczema; CTCL
Generalized pustular 
psoriasis
Subcorneal pustular dermatosis, Pemphigus foliaceus, Impetigo, Migratory 
necrolytic erythema, widespread candidal infection
Localized pustular 
psoriasis
Infected eczema, fungal infection on the soles
Acral involvement Herpes simplex, streptococcal and candidal infections
Seborrheic psoriasis Seborrheic dermatitis
Childhood psoriasis Dermatitis; candidal infection
Inverse Seborrheic dermatitis; fungal infections; erythrasma
Adopted from [20].
Table 1. 
Differential diagnosis.
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1. Mild to moderate disease (most of the patients, affecting less than 5% of the body surface 
area and sparing the genitals, hands, feet, and face) (Figure 2) [21].
2. First-line: [30–33]
• Topical corticosteroids.
• Topical vitamin D analogs—calcipotriene (Dovonex) and calcitriol (Vectical); as 
monotherapy or in combination with phototherapy to treat psoriasis in patients who 
have 5–20% body surface involvement.
• Tazarotene—teratogenic topical retinoid; as effective as topical corticosteroids in alle-
viating symptoms of psoriasis, but it is associated with a longer disease-free interval.
• Calcineurin inhibitors—tacrolimus (Protopic) and pimecrolimus (Elidel); first-
line treatments for facial and flexural psoriasis; uncommon adverse events (skin 
malignancy and lymphoma).
3. Second line: [32]
• Salicylic acid
Figure 2. 
Summary of treatment.
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• Coal tar
• Anthralin
4. Severe psoriasis (more than 5% of the body surface area or involving hands, feet, face, or 
genitals) [35].
5. First line systemic therapy: methotrexate, cyclosporine, acitretin, and biologic 
therapies.
6. Second line systemic therapy: azathioprine, hydroxyurea, sulfasalazine, leflunomide, 
tacrolimus, and thioguanine.
7. Biologic therapy (treatment of moderate to severe psoriasis and in psoriatic arthritis).
8. Tumor necrosis factor (TNF) inhibitors (risk of serious infection, including 
tuberculosis):
• Adalimumab
• Etanercept: often used in conjunction with methotrexate
• Infliximab: the most rapid clinical response; sustained response and improvements 
in quality of life.
9. Interleukin inhibitors: Ustekinumab (Stelara)—new and well tolerated in clinical 
trials [34].
Although psoriasis is usually benign, it is a lifelong illness with remissions and 
exacerbations. About 10% of cases progresses to arthritis. Men and women with 
severe psoriasis died 3.5 and 4.4 years earlier, compared with men and women 
without the disease, respectively [36].
In a population-based cross-sectional study of psoriasis patients and matched 
controls without psoriasis, those with more extensive psoriasis were at greater 
risk for major medical comorbidities, such as cardiovascular disease, chronic lung 
disease, diabetes mellitus, kidney disease, Crohn’s disease, bullous pemphigoid, 
vitiligo, and joint problems [37, 38].
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